Filing Flows

Filing Flows › Companies › Aspira Women's Health › Cash flow

Aspira Women's Health cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.0M in Q2 2026 · −$4.6M over twelve months

Operating cash flow−$2.0M
Free cash flow−$2.0M
Cash conversion cycle-144 days

Analysis

In Q2 2026, Aspira Women's Health generated −$2.0M of operating cash flow. That is $276K less than in Q2 2025 (−$1.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$4.6M; the largest uses were operating cash flow ($4.6M), net borrowing (+) / repaid (−) ($235K); besides operations, cash came from other financing ($4.3M); the cash balance fell by $1.1M.

Operating cash flow was −$2.0M against net income of −$2.4M. The largest differences: other liabilities −$1.3M, payables +$785K, accrued liabilities +$282K.

Its cash conversion cycle was -144 days (receivables 65 + inventory 26 − payables 235): suppliers fund its working capital.

Free cash flow

Aspira Women's Health: free cash flow by quarterAspira Women's Health: free cash flow by quarter−$2.9MQ3 2024−$1.0MQ4 2024−$3.1MQ1 2025−$1.7MQ2 2025−$212KQ3 2025−$2.0MQ4 2025−$359KQ1 2026−$2.0MQ2 2026
Operating cash flow less capital spending.
Aspira Women's Health: operating cash flow against capital spendingAspira Women's Health: operating cash flow against capital spendingOperating cash flowCapital spending−$2.9M$2KQ3 2024−$1.0M$0Q4 2024−$3.1M$0Q1 2025−$1.7M$0Q2 2025−$212K$0Q3 2025−$2.0M$8KQ4 2025−$359K$0Q1 2026−$2.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.0M, Capital spending $0.

Capital allocation, year by year

Aspira Women's Health: where the cash came from (up) and went (down), by fiscal yearAspira Women's Health: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$27.4MFY2021: Net borrowing −$198KFY2021: Shares issued $49.0MFY2021: Capital spending −$184K$49.0MFY2021FY2022: Operating cash flow −$31.1MFY2022: Net borrowing −$261KFY2022: Shares issued $9.0MFY2022: Capital spending −$232K$9.0MFY2022FY2023: Operating cash flow −$15.9MFY2023: Net borrowing $1.0MFY2023: Shares issued $202KFY2023: Capital spending −$24K$1.2MFY2023FY2024: Operating cash flow −$12.1MFY2024: Net borrowing −$93KFY2024: Capital spending −$37KFY2024FY2025: Operating cash flow −$7.0MFY2025: Net borrowing $1.1MFY2025: Capital spending −$16K$1.1MFY2025
Over these 5 years operating cash flow totalled −$93.5M; the largest uses were operating cash flow ($93.5M) and net borrowing ($552K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$477K
Debt$1.7M
Net debt$1.2M
Due within a year$744K
Cash runway1 month

Aspira Women's Health is burning cash: its operations consume cash, a free cash flow of −$4.6M a year at the current rate against $477K of cash and investments: a runway of about 1 month; $744K of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Aspira Women's Health: sources (+) and uses (−) of cash, Q2 2026Aspira Women's Health: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.0MOther financing$1.4MCash drawn (+) / kept (−)$867KNot reconciled−$150KNet borrowing (+) / repaid (−)−$59K
Aspira Women's Health: sources (+) and uses (−) of cash, TTM to Q2 2026Aspira Women's Health: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$4.6MOther financing$4.3MCash drawn (+) / kept (−)$1.1MNot reconciled−$551KNet borrowing (+) / repaid (−)−$235K

From profit to cash

Aspira Women's Health: net income to operating cash flow, Q2 2026Aspira Women's Health: net income to operating cash flow, Q2 2026Net income−$2.4MDepreciation & amortization$40KStock-based pay$19KGains on disposals$1KReceivables−$61KInventory$61KPayables$785KAccrued liabilities$282KPrepaid and other assets$122KOther liabilities−$1.3MOperating cash flow−$2.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20266526235-144
Q1 20266028161-73
Q4 20255231177-94
Q3 20255228177-98
Q2 20254528167-94
Q1 20254137227-149
Q4 20244433253-176
Q3 20245526229-148

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.0M—−$59K$867K−$2.0M
Q1 2026−$359K—−$52K$411K−$359K
Q4 2025−$2.0M−$8K−$59K$2.1M−$2.0M
Q3 2025−$212K—−$58K−$2.3M−$212K
Q2 2025−$1.7M—−$58K$1.8M−$1.7M
Q1 2025−$3.1M—$1.3M−$1.5M−$3.1M
Q4 2024−$1.0M—−$58K$364K−$1.0M
Q3 2024−$2.9M−$2K−$18K−$1.2M−$2.9M

Aspira Women's Health: income statement and cash flow

Aspira Women's Health, Q2 2026: revenue $2.0M (-15% year over year), operating margin -89.7%. The chart follows the revenue to costs, profit and cash.

Aspira Women's Health: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.